|
|
|
The diagnostics industry is undergoing a period of rapid transformation. Competitive pressures in the
basic core hospital laboratory are forcing large companies to reevaluate their franchises and seek
high-growth areas in which to compete. Smaller companies, armed with exciting innovations in POC
technologies and new assays, are confronting increased regulatory scrutiny, lengthy drug-like
development pathways, and a questionable reimbursement landscape. For all companies, capturing
value from the hype of personalized medicine in the form of novel biomarkers has been
difficult as scientific and commercial hurdles slow the progress of the field. Future
success in this industry will likely hinge on two main thrusts: 1) partnering approaches
between companies (diagnostic to diagnostic and drug to diagnostic), and 2) developing
compelling value-based pricing arguments with subsequent reimbursement from payers.
Health Advances is assisting a wide range of companies in both of these thrusts.
Health Advances' clients include large and small diagnostic and drug discovery tools companies as
well as reference laboratories. From traditional clinical laboratory tests, to new molecular biomarkers,
to cutting-edge imaging technology, to emerging translational technologies, Health Advances is at the
forefront in advising companies on how to extract the value their tests can create for the healthcare system.
- Opportunity identification and application screening
- Technology development
- Product positioning
- Value-based pricing, reimbursement, and system economics
- Sales force deployment and marketing strategy
- Deal preparation, M&A, and partner strategies
- Corporate and business unit strategy
|
|
 |
|
|
|
|
|
 learn more
about our work with diagnostic products.
read
our article on biomarker development.
|
|
|
|
|
 |
|
|
